Last updated 17 Dec 2017, 05:30 AM
Associated community Adrenomyeloneuropathy
RGI/RareShare Ask the Experts Podcast Series-Adrenomyeloneuropathy Syndrome
Rare Genomics Institute and RareShare are proud to invite you for the upcoming podcast discussing:
Living with Adrenomyeloneuropathy (AMN) -A Clinical & Research Perspective
TIME: 10:00 AM-11:00 AM EST (7:00 AM-8:00 AM PST, 2:00 PM-3:00PM GMT)
Here is that chance!
The first 25 minute segment will feature medical scientists/clinicians discussing the latest developments in AMN regarding genomics and biotechnology research, while the remaining 20 minutes will feature guest speakers will answer your questions/concerns/issues.
**Here is your chance to ask any question you may have about Adrenomyeloneuropathy?
Submit your question(s) NOW with this form (RareShare Adrenomyeloneuropathy Podcast Registration form) and/or register to attend the program.**
Register here to reserve your spot in the call!
PS. If you cannot participate but would like to ask our experts any questions, please submit them here. The transcript and recording will be posted on the homepage of Rare Genomics and RareShare AMN Syndrome Community after the live Q&A.
MODERATOR: Imogen Crispe
Rare Genomics Podcast Organizer
Meet our Panel of Experts
Dr. Paul Orchard, MD
Professor of Pediatrics in the Division of Blood and Marrow Transplantation (BMT) at the University of Minnesota
Medical Director of the Inherited Metabolic and Storage Disease Bone Marrow Transplantation Program
Dr Orchard attended medical school at Brown University, served his residency at the University of Wisconsin - Madison, in pediatrics, and held a fellowship at the University of Minnesota.
Dr. Orchard is interested in the use of blood and marrow transplantation (BMT) and potentially other cell therapies for inherited metabolic diseases, like Hurler syndrome and adrenoleukodystrophy. He has developed new therapies specifically for this group of patients with the goal of minimizing neurologic deterioration during the transplant process, including the use of anti-oxidants, reduced intensity transplant regimens and combinations of therapy such as transplant and enzyme replacement. This work also benefits other children undergoing transplant, particularly in regards to our commitment to minimize the side effects of transplantation.
In addition to his clinical work with patients who have inherited metabolic diseases, Dr. Orchard is also engaged in more basic research studies in regard to determining strategies to enhance the delivery of enzymes to the brain and the peripheral nervous system for patients who lack specific enzymes. In addition, he is interested in testing other types of stem cells that may improve outcomes for patients with inherited diseases, including gene therapy approaches. He also leads research and clinical care for patients with osteopetrosis, an inherited disorder leading to increased density of bone, for which BMT is a treatment option. Dr. Orchard is considered an international expert in this disorder and its treatment.
Dr. William B. Rizzo, MD
Professor, Division of Inherited Metabolic Diseases at the University of Nebraska Medical Center
Dr Rizzo attended medical school at the University of Illinois, Chicago, completed his residency at John Hopkins Hospital in Baltimore, Maryland, and was a fellow at the National Institutes of Health. He has been in practice for more than 20 years.
Dr Rizzo’s research is directed at understanding the genetic and biochemical basis of inherited metabolic diseases, with a particular emphasis on disorders of lipid metabolism, and diseases which cause a variety of symptoms involving the brain, nerves, skin and eyes. The investigations in his lab range from basic research on biochemical pathways to discovering unrecognized genetic diseases that affect metabolism in children and adults. Dr Rizzo is particularly interested in Sjogren-Larsson Syndrome and his research has identified the cause of several genetic diseases, and led to the development of new diagnostic tests and treatment approaches.